4.7 Article

Recurrence and Survival Rates for 1400 Early Breast Tumors Treated with Intraoperative Radiation Therapy (IORT)

Journal

ANNALS OF SURGICAL ONCOLOGY
Volume 29, Issue 6, Pages 3726-3736

Publisher

SPRINGER
DOI: 10.1245/s10434-021-11295-1

Keywords

-

Funding

  1. Departments of Radiation Oncology, Radiology, and Surgery

Ask authors/readers for more resources

In this study, we observed that intraoperative radiotherapy (IORT) resulted in similar local, regional, and distant recurrence rates compared to the literature, but higher than standard whole breast radiation therapy, hypofractionated treatment, or accelerated partial breast irradiation. The advantages of IORT include convenience, reduced exposure to medical environments, and low complication rates.
Introduction Intraoperative radiotherapy (IORT) permits accurate delivery of radiation therapy directly to the tumor bed. We report local, regional, and distant recurrence data along with overall and breast cancer-specific survival for 1400 tumors treated with x-ray IORT. Methods A total of 1367 patients with 1400 distinct tumors were enrolled in a registry trial. All received breast conservation surgery and low-energy 50 kV x-ray IORT. To be eligible for excision plus IORT as the only local treatment, histopathology had to confirm tumor size <= 30 mm, margins >= 2 mm, negative lymph nodes, and no extensive lymphovascular invasion. Patients who failed any parameters were referred for additional surgery and/or whole breast radiation therapy (WBRT). Results There were 64 ipsilateral local recurrences, 60 were in the IORT only group, 7 axillary recurrences, and 7 distant recurrences. Forty-one local recurrences were within the same quadrant as the index cancer. Twenty-three were in different quadrants. With 62 months of median follow-up, the 5-year Kaplan-Meier probability of any event for all 1400 tumors was 5.27%. For 1175 patients who received IORT only, it was 5.98%. For favorable subtypes, it ranged from 2.41 to 4.31%. Multivariate analysis revealed that biologic subtype luminal A and the addition of WBRT significantly reduced the risk of local recurrence. Conclusions The local, regional, and distant recurrence rates observed were comparable to those reported in the literature for IORT but higher than those reported for standard forms of WBRT, hypofractionated treatment, or APBI. IORT benefits include convenience, decreased exposure to medical environments, and low complication rates.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Medicine, General & Internal

Knowledge user survey and Delphi process to inform development of a new risk of bias tool to assess systematic reviews with network meta-analysis (RoB NMA tool)

Carole Lunny, Areti Angeliki Veroniki, Brian Hutton, Ian White, Jpt Higgins, James M. Wright, Ji Yoon Kim, Sai Surabi Thirugnanasampanthar, Shazia Siddiqui, Jennifer Watt, Lorenzo Moja, Nichole Taske, Robert C. Lorenz, Savannah Gerrish, Sharon Straus, Virginia Minogue, Franklin Hu, Kevin Lin, Ayah Kapani, Samin Nagi, Lillian Chen, Mona Akbar-nejad, Andrea C. Tricco

Summary: This study aimed to develop a risk of bias (RoB) tool for assessing network meta-analysis (NMA) and gather opinions from knowledge users. The Delphi process and knowledge user survey identified the content of the RoB NMA tool and revealed a preference for assessing both individual NMA results and authors' conclusions.

BMJ EVIDENCE-BASED MEDICINE (2023)

Article Oncology

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984

Joseph W. Kim, Rana R. McKay, Marc R. Radke, Shilin Zhao, Mary-Ellen Taplin, Nancy B. Davis, Paul Monk, Leonard J. Appleman, Primo N. Lara, Ulka N. Vaishampayan, Jingsong Zhang, Asit K. Paul, Glenn Bubley, Eliezer M. Van Allen, Serhan Unlu, Ying Huang, Massimo Loda, Geoffrey I. Shapiro, Peter M. Glazer, Patricia M. LoRusso, S. Percy Ivy, Yu Shyr, Elizabeth M. Swisher, Daniel P. Petrylak

Summary: The study investigated the clinical outcomes of combining Cediranib with olaparib in patients with prostate cancer. The results showed that the combination improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer compared to olaparib alone. However, it was also associated with a higher incidence of adverse events.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Letter Oncology

The long-lasting challenge of predicting response to poly (ADP-ribose) polymerase inhibitors Reply

Bradley J. Monk, Keiichi Fujiwara, David M. O'Malley, Robert L. Coleman, Iain A. McNeish, Kevin K. Lin, Stephanie Hume, Rebecca S. Kristeleit

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

Eve Rodler, Priyanka Sharma, William E. Barlow, Julie R. Gralow, Shannon L. Puhalla, Carey K. Anders, Lori Goldstein, Debu Tripathy, Ursa A. Brown-Glaberman, Thu-Tam Huynh, Christopher S. Szyarto, Andrew K. Godwin, Harsh B. Pathak, Elizabeth M. Swisher, Marc R. Radke, Kirsten M. Timms, Danika L. Lew, Jieling Miao, Lajos Pusztai, Daniel F. Hayes, Gabriel N. Hortobagyi

Summary: PARP inhibitors are effective in germline BRCA1/2-mutated metastatic breast cancer. This study demonstrates that adding veliparib to cisplatin improves progression-free survival in patients with BRCA-like metastatic triple-negative breast cancer.

LANCET ONCOLOGY (2023)

Article Oncology

What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women

Ann Oluloro, Sarah M. Temkin, Jonathan Jackson, Elizabeth M. Swisher, Liz Sage, Kemi Doll

Summary: This study comprehensively assessed gynecologic cancer clinical trial protocols and found that they lack design elements that provide high value to Black individuals, such as lifestyle risk factors, ancestry, and remuneration. Inclusion of these valued items should be considered in efforts to improve diversity in clinical trial enrollment among Black individuals.

GYNECOLOGIC ONCOLOGY (2023)

Article Cell Biology

Fanconi anemia-associated chromosomal radial formation is dependent on POLθ-mediated alternative end joining

Colette B. Rogers, Rachel E. Kram, Kevin Lin, Chad L. Myers, Alexandra Sobeck, Eric A. Hendrickson, Anja-Katrin Bielinsky

Summary: Activation of the Fanconi anemia (FA) pathway is crucial for preventing chromosome translocations referred to as "radials" after treatment with mitomycin C (MMC). Radials induced by MMC are dependent on DNA polymerase theta (POLq)-mediated alternative end joining (A-EJ) in FA-deficient cells, specifically involving POL theta and DNA ligase III. Blocking POLq in FA-deficient cells eliminates radials and leads to the accumulation of breaks at common fragile sites. These findings provide mechanistic insights into the formation of radials and offer potential therapeutic strategies for FA pathway-deficient cancers using POLq inhibitors.

CELL REPORTS (2023)

Article Medicine, General & Internal

Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10

Olivier Colomban, Elizabeth M. Swisher, Rebecca Kristeleit, Iain McNeish, Ronnie Shapira-Frommer, Sandra Goble, Kevin K. Lin, Lara Maloney, Gilles Freyer, Benoit You

Summary: Mathematical modeling of early CA-125 kinetics can be used as an indicator of rucaparib efficacy in recurrent ovarian carcinoma patients. The KELIM-PARP score is associated with treatment response and progression-free survival. This study suggests the potential use of this strategy in selecting patients for PARPi-based treatment regimens.

EBIOMEDICINE (2023)

Review Oncology

The Potential Effect of General Anesthetics in Cancer Surgery: Meta-Analysis of Postoperative Metastasis and Inflammatory Cytokines

Ru Li, Mousumi Beto Mukherjee, Zhaosheng Jin, Hengrui Liu, Kevin Lin, Qiuyue Liu, James P. Dilger, Jun Lin

Summary: This meta-analysis examined the effect of general anesthetics on metastasis and recurrence after cancer surgery. It showed that propofol-based total intravenous anesthesia is associated with a lower risk of metastasis/recurrence and lower IL-6 level compared to inhalational anesthesia. Pre-clinical studies confirmed these findings and explored potential mechanisms.

CANCERS (2023)

Article Oncology

Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing

Heidi J. Gray, Payel Chatterjee, Rachele Rosati, Lauren R. Appleyard, Grace J. Durenberger, Robert L. Diaz, Hallie A. Swan, Danielle Peretti, Maddy Pollastro, Trevor Ainge, Katannya Kapeli, Shalini Pereira, Astrid L. Margossian, Kalyan Banda, Barbara A. Goff, Elizabeth M. Swisher, Brady Bernard, Christopher J. Kemp, Carla Grandori

Summary: This article describes a remarkable response to targeted therapy in a patient with platinum-resistant, advanced low-grade serous ovarian cancer. Genomic analysis did not provide obvious therapeutic options, but a drug sensitivity assay identified several potential therapies. This case highlights the clinical utility of ex vivo drug testing of patient-derived tumor organoids as a new approach to identify personalized therapies.

NPJ PRECISION ONCOLOGY (2023)

Editorial Material Oncology

ASO Author Reflections: Intraoperative Radiation Therapy (IORT): Will It Survive in the USA?

Melvin J. Silverstein, Brian Kim, Shane Lloyd, Peter Chen, Kevin Lin

ANNALS OF SURGICAL ONCOLOGY (2023)

Editorial Material Obstetrics & Gynecology

Sertoli-Leydig cell tumor associated with a germline DICER1 pathogenic variant diagnosed during pregnancy: Considerations for treatment, surveillance, and prevention

Joyce Y. Wang, Kimberly K. Ma, Daniel J. Reiter, Ana Torvie, Elizabeth M. Swisher

GYNECOLOGIC ONCOLOGY REPORTS (2023)

Meeting Abstract Oncology

Targeted CRISPR screen to identify synthetic lethal combinations between APOBEC3B and DNA repair

Bojana Stefanovska, Kevin Lin, Benjamin Troness, Chad Myers, Reuben Harris

CANCER RESEARCH (2023)

Meeting Abstract Clinical Neurology

CIRCADIAN FRAGMENTATION AND STABILITY DISTINGUISH EMPLOYMENT STATUS

David Glickenstein, Avinash Karamchandani, Camille Korbut, Michelle Bang, Alexa Aucoin, Leah Callovini, Kevin Lin, Patricia Haynes

SLEEP (2023)

Meeting Abstract Oncology

Intraoperative Radiation Therapy (IORT) with or without Whole-breast Treatment (WBRx)

Katherine Kramme, Emily Welker, Oana Andreea Raicu, Melvin Silverstein, Sadia Khan, Peter Chen, Kevin Lin, Brian Kim, Shane Lloyd

ANNALS OF SURGICAL ONCOLOGY (2023)

Meeting Abstract Oncology

The Selection of Breast Cancer Patients for Intraoperative Radiation Therapy (IORT) Using American Society of Therapeutic Radiation Oncology (ASTRO) Category

Emily Welker, Peter Chen, Sadia Khan, Brian Kim, Katherine Kramme, Kevin Lin, Shane Lloyd, Oana Andreea Raicu, Melvin Silverstein

ANNALS OF SURGICAL ONCOLOGY (2023)

No Data Available